About us and our history

Our story

Now part of Feedback plc, TexRAD was born when researchers from the Brighton and Sussex Medical School (BSMS) and the University of Sussex jointly developed innovative and cost-effective medical imaging software with the aim of helping clinicians manage important diseases such as cancer. In April 2011 TexRAD’s founders entered into partnership with leading medical imaging companies Cambridge Computing Imaging Limited (also now part of the Feedback group), Imaging Equipment Limited, and Miles Medical Pty Limited to form TexRAD Limited. The company was launched with a vision to be able to equip health care providers with accurate and efficient technology that enhanced overall patient care and quality of service using heterogeneity and texture analysis. We believe that TexRAD, for the first time ever, offers the opportunity to derive ‘textures’ from routine diagnostic images and highlight anomalies not apparent to the human eye. It has the potential to become an imaging biomarker for prognosis and treatment response in cancer patients. TexRAD is unique in being extremely easy to integrate within existing hospital imaging systems without the need for any hardware modifications. In April 2014, TexRAD joined Cambridge Computed Imaging Ltd as part of Feedback plc.

The Team

Dr Balaji Ganeshan

Science Director

Balaji has been the Science Director of TexRAD since incorporation and before that was instrumental in the invention, research and development of the original IP in his various capacities as a PhD researcher, post-doctorate researcher, principal investigator and project manager. He now takes the lead in sales and marketing of Texrad in the clinical research market and is also a Senior Research Associate at the Institute of Nuclear Medicine at the University College London, UK, and is a Visiting Research Fellow with the Brighton & Sussex Medical School, University of Sussex.

Mike Hayball

Technical Director

Mike is the software architect and has been instrumental in the development of TexRAD as a research platform. He started his career as a medical physicist at Addenbrooke’s Hospital in Cambridge where he took his MSc in Radiation Physics. At Addenbrooke’s he worked on the first CT perfusion implementation for modern CT scanners, leading to publication in The Lancet in 1991. From there he went on to work on cardiac imaging at Papworth Hospital, working with Stephen Brown on ECG-triggered spiral CT. In 2001, Mike joined Stephen Brown to form CCI where he splits his time as Managing Director.

Our research customers

What the experts are saying about us:

"The preliminary TexRAD results were impressive, I was able to identify an invasive breast cancer focus within a larger area of pre-operative, non-invasive disease"
- Dr Olga Strukowska, Consultant Radiologist of the Western Sussex Hospitals Trust, Worthing

“TexRAD provides unique tumor information, which in addition to standard morphological assessment, could improve therapeutic assessment in renal cancer treated with tyrosine kinase inhibitors. The preliminary results are encouraging for its use as a predictive biomarker in this clinical context”
- Dr Vicky Goh, Consultant Radiologist at Mount Vernon Hospital, Northwood

“TexRAD has the potential to assist clinical decision-making by predicting the risk of disease and assessing
the prognosis for cancer patients”
- Professor Ken Miles, Consultant Radiologist

"TexRAD software has allowed us to predict survival outcomes in several different tumors and treatment situations in a research setting. The data acquisition process and analysis has been streamlined for large studies, and the applications and support by TexRAD software engineers and leaders has led to some amazing results"
- Andrew D. Smith M.D.Ph.D., Director of Radiology Research, Body Radiologist and Oncologic Imager Assistant Professor

"TexRAD is a very powerful software analytical tool that allows for in-depth evaluation of solid tumors for predictive, prognostic and treatment response categorization. We have used it in our Core Imaging lab on multiple occasions to help accelerate drug development for our pharmaceutical clients. It truly offers advanced information unlike any other technology in the field!"
- Ronald L Korn MD PhD, CEO and Founder Imaging Endpoints Core Lab


UK

Brighton & Sussex University Hospitals

NHS Trust, UK

Kings College

London, UK

Paul Strickland Scanner Centre

Mount Vernon Hospital, Middlesex, UK

Royal Surrey County Hospital

Guildford, UK

The Institute of Cancer Research

Royal Marsden Hospital, Surrey, UK

University of Cambridge

Cambridge, UK

University College London Hospitals

UK

Velindre Cancer Centre

Cardiff, UK

EUROPE

Aarhus University Hospital

Aarhus, Denmark

European Institute of Oncology

Milan, Italy

Oslo University Hospitals

Oslo, Norway

University of Rome, Sapienza

Rome, Italy

Universitatsspital Basel

Switzerland

Centre Hospitalier Universitaire de Reims

Reims, France

Evangelische Lungen Klinik

Berlin, Germany

Haukeland University Hospital

Bergen, Norway

Gustave Roussy Cancer Centre

Paris, France

Descartes University

Paris, France

Centre Hospitalier Universitaire de Grenoble

Grenoble, France

University of Brescia

Brescia, Italy

Turku University hospital

Turku, Finland

NORTH AMERICA

Johns Hopkins University

Baltimore, MD, USA

Georgetown University Hospital

Washington DC, USA

University of Mississippi Medical Centre

Mississippi, USA

Massachusetts General Hospital

Boston, USA

Scottsdale Clinical Research Institute

Scottsdale Healthcare AZ, USA

University of Wisconsin

Madison, USA

Indiana University

Indiana, USA

St Jude Children's Research Hospital

Memphis, USA

Sunnybrook Health Sciences Center

Ontario, Canada

McGill University

Montreal, Canada

REST OF THE WORLD

Tata Memorial Hospital

Mumbai, India

Peking Union Medical College Hospital

Peking, China

University of Tokyo

Tokyo, Japan

Seoul National University Bundang Hospital

Seoul, South Korea

Princess Alexandra hospital

Brisbane, Australia